NASDAQ:MYOK MyoKardia (MYOK) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free MYOK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$224.91▼$224.9150-Day Range$222.81▼$224.9152-Week Range$42.65▼$225.00VolumeN/AAverage Volume752,969 shsMarket Capitalization$11.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get MyoKardia alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About MyoKardia Stock (NASDAQ:MYOK)MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. MYOK Stock News HeadlinesMarch 27, 2024 | seekingalpha.comFULC Fulcrum Therapeutics, Inc.March 16, 2024 | seekingalpha.comCytokinetics: CEO Talks Down Buyout ProspectsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 27, 2024 | uk.finance.yahoo.comQ4 2023 Fulcrum Therapeutics Inc Earnings CallFebruary 27, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023February 27, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023February 16, 2024 | cbsnews.comIf heart disease runs in your family, talk to your doctor about HCMNovember 29, 2023 | finance.yahoo.comBristol Myers pours $100M into RNA drugs for cardiovascular diseasesMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…November 29, 2023 | msn.comAvidity and BMS enter $2.3bn deal for cardiovascular targetsNovember 28, 2023 | msn.comWhy Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?November 28, 2023 | msn.comAvidity’s stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone paymentsNovember 22, 2023 | forbes.comHow Viz.ai Uses Artificial Intelligence To Treat Stroke Patients FasterOctober 24, 2023 | benzinga.comWhy LianBio Stock Is Ripping Higher TodayOctober 24, 2023 | msn.comWhy Is LianBio (LIAN) Stock Up 130% Today?October 24, 2023 | msn.comWhy LianBio Stock Is Skyrocketing TodayOctober 24, 2023 | finance.yahoo.comLianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian MarketsOctober 9, 2023 | msn.comBristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 BOctober 4, 2023 | bizjournals.comPeninsula biotech company looks to pump new life into heart disease treatmentsAugust 31, 2023 | msn.comFulcrum Therapeutics (FULC) Price Target Increased by 30.97% to 10.78July 27, 2023 | finance.yahoo.comCutera, Inc. Appoints Taylor Harris as Chief Executive OfficerJuly 27, 2023 | markets.businessinsider.comCutera Names Taylor Harris As CEO, Shares GainJuly 27, 2023 | marketwatch.comCutera Names Taylor Harris CEO, Ending Succession Tussle >CUTRJuly 11, 2023 | finance.yahoo.comAbivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of DirectorsJuly 11, 2023 | markets.businessinsider.comEQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of DirectorsJuly 10, 2023 | investing.comKorporatsiya VSMPO AVISMA PAO (VSMO)June 9, 2023 | uk.finance.yahoo.comHypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2023See More Headlines Receive MYOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOK CUSIPN/A CIK1552451 Webwww.myokardia.com Phone650-741-0900FaxN/AEmployees318Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.99% Return on Assets-42.42% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$33.56 million Price / Sales357.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book25.59Miscellaneous Outstanding Shares53,323,000Free FloatN/AMarket Cap$11.99 billion OptionableOptionable Beta1.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Tassos Anastasios E. Gianakakos (Age 47)Pres, CEO & Director Comp: $987.02kMr. Taylor C. Harris (Age 44)Chief Financial Officer Comp: $604.47kDr. Robert S. McDowell (Age 62)Chief Scientific Officer Comp: $579.19kMr. Jake B. Bauer (Age 41)Chief Bus. Officer Comp: $547.2kMr. William C. Fairey Jr. (Age 54)Chief Commercial Officer & Exec. VP Comp: $905.02kDr. Leslie LeinwandCo-FounderDr. Christine E. Seidman (Age 67)Co-Founder Dr. Jonathan G. SeidmanCo-FounderDr. James A. Spudich (Age 78)Co-Founder Michelle CorralExec. Director of Corp. Communications & Investor RelationsMore ExecutivesKey CompetitorsSarepta TherapeuticsNASDAQ:SRPTDr. Reddy's LaboratoriesNYSE:RDYUnited TherapeuticsNASDAQ:UTHRKaruna TherapeuticsNASDAQ:KRTXCatalentNYSE:CTLTView All Competitors MYOK Stock Analysis - Frequently Asked Questions How were MyoKardia's earnings last quarter? MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.16. What other stocks do shareholders of MyoKardia own? Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and RTX (RTX). This page (NASDAQ:MYOK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyoKardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.